GlassScriptPhysician profile
Lien T Nguyen
NPI 1508906033
$15,573.22
in general payments reported to CMS, 2019-2025
57 companies · $7,245 in 2025
The $7,245 reported for 2025 was more than what 99% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,699 · 2022: $2,130 · 2023: $2,444 · 2024: $2,054 · 2025: $7,245.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,694 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $4,050.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,693.83 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $4,050.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $5,184.08 | 2021-2025 | Tremfya, Stelara, Simponi Aria |
| Aimmune Therapeutics, INC. | $1,227.08 | 2024-2025 | Zenpep |
| Genzyme Corporation | $780.76 | 2021-2025 | |
| Abbvie INC. | $770.02 | 2022-2025 | |
| Madrigal Pharmaceuticals | $754.03 | 2024-2025 | Rezdiffra, Resmetirom |
| Celgene Corporation | $724.81 | 2021-2024 | Zeposia, Pomalyst |
| Pharmacyclics LLC, An Abbvie Company | $529.05 | 2021-2023 | Imbruvica, Epkinly |
| Pfizer INC. | $370.32 | 2021-2025 | |
| Seagen INC. | $327.90 | 2021-2022 | |
| E.R. Squibb & Sons, L.L.C. | $320.69 | 2021-2023 | Zeposia |
| Medtronic, INC. | $290.48 | 2024-2025 | Gi Genius, Barrx |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $290.46 | 2023-2025 | Xifaxan |
| Merck Sharp & Dohme LLC | $283.54 | 2021-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $269.96 | 2023-2025 | Entyvio, Eohilia |
| Regeneron Healthcare Solutions, INC. | $254.47 | 2022-2025 | Dupixent |
Show all 57 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lien Nguyen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.